Skip to main content
. 2017 Nov 22;177(1):133–144. doi: 10.1007/s00431-017-3046-1

Fig. 4.

Fig. 4

Cost-effectiveness acceptability curve at different willingness to pay levels for RSV prophylaxis based on 5000 iterations. Results of probabilistic sensitivity analysis with per infant incremental cost-effectiveness in a cost-effectiveness acceptability curve of targeted RSV prophylaxis (blue line) vs. standard care (no RSV prophylaxis, red line) in moderately preterm infants 32–35 weeks gestational age